

Anti-BAFF & IL-17A Antibody (Tibulizumab)

Introduction

Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used in the study of autoimmune diseases.

Product parameters

Alternative Names	LY3090106
Target Accession	Q9Y275 & Q16552
Target	BAFF & IL-17A
CAS number	1849636-24-3
Molecular Weight	201.44 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG4
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human IL 17A mFC at 2 ug/mL can bind Anti-BAFF & IL-17A Reference Antibody (Tibulizumab), EC50=0.03561 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

